Pregabalin
- Generic Name
- Pregabalin
- Brand Names
- Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H17NO2
- CAS Number
- 148553-50-8
- Unique Ingredient Identifier
- 55JG375S6M
- Background
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
- Indication
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
- Associated Therapies
- -
Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6498
- Registration Number
- NCT01587339
Pregabalin Reduce the Sevoflurane Requirement
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 42
- Registration Number
- NCT01571804
- Locations
- 🇪🇬
Mansoura University Hospitals, Mansoura, DK, Egypt
Pregabalin on Interleukin-6 Levels in Living Donor Kidney
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 40
- Registration Number
- NCT01529190
- Locations
- 🇧🇷
Federal University of Sao Paulo, Sao Paulo, Brazil
Behavioral Effects of Pregabalin and Cannabis
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Joshua A. Lile, Ph.D.
- Target Recruit Count
- 30
- Registration Number
- NCT01511640
- Locations
- 🇺🇸
Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States
Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 54
- Registration Number
- NCT01496690
- Locations
- 🇩🇰
Aalborg University Hospital, Psychiatry, Aalborg, Denmark
A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 114
- Registration Number
- NCT01485094
- Locations
- 🇵🇱
POL004, Lublin, Poland
🇭🇺HUN008, Szikszo, Hungary
🇭🇺HUN003, Győr, Hungary
Preventing Pain After Heart Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Barts & The London NHS Trust
- Target Recruit Count
- 150
- Registration Number
- NCT01480765
- Locations
- 🇬🇧
Pain and Ananesthesia Research Centre, Barts and The London NHS Trust, London, United Kingdom
Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Julian Taylor Green
- Target Recruit Count
- 82
- Registration Number
- NCT01479556
- Locations
- 🇪🇸
Hospital Nacional de Parapléjicos de Toledo, Toledo, Spain
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 217
- Registration Number
- NCT01474772
- Locations
- 🇺🇸
HealthCare Partners Medical Group, Los Angeles, California, United States
🇺🇸IDS Pharmacy, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- Conditions
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2021-01-20
- Target Recruit Count
- 605
- Registration Number
- NCT01463306
- Locations
- 🇺🇸
Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States
🇺🇸Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇨🇳The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.